Entera Bio raises $10 million from BVF Partners in private placement

Entera Bio Ltd. (NASDAQ: ENTX) announced it has entered into a securities purchase agreement for a private placement led by funds affiliated with BVF Partners L.P., according to a company statement.

The private placement is expected to close on or about April 2, 2026, subject to customary closing conditions. The company agreed to issue and sell 7,827,789 units at $1.2775 per unit, generating gross proceeds of approximately $10.0 million before offering expenses.

Each unit consists of one ordinary share and one five-year warrant to purchase 1.5 ordinary shares at an exercise price of $1.24 per share, representing an 11.7% premium to the company's closing price on March 31, 2026. If all warrants are exercised for cash, the company could receive additional proceeds of approximately $14.5 million, bringing total potential proceeds to approximately $24.5 million.

The warrants will become exercisable six months following the closing date and expire five years after issuance. They will be exercisable only for cash except in certain circumstances. Pre-funded warrants included in the placement will have an exercise price of NIS 0.0000769 per share and will be immediately exercisable upon issuance without expiration.

Entera plans to use the net proceeds along with existing cash to support activities related to initiating a phase 3 study of EB613 in postmenopausal women with osteoporosis and for general working capital and corporate purposes.

The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws.

Entera Bio is a clinical-stage company developing oral peptide and protein replacement therapies using its N-Tab technology platform. The company's lead candidate EB613 is an oral tablet for osteoporosis treatment.

You May Also Be Interested In

• Fermi strikes 2.6 GW power deal with Hillcore for Texas AI campus
• Snail, Inc. (SNAL) Reports Q3 Loss of $0.36
• NovaGold and Paulson hire advisors for Donlin Gold project financing